MS Walking Treatment
NHS England Rolls Out Fampridine to Improve Walking for MS Patients
Anonymous
Key Points
1
Explicit eligibility criteria by EDSS score: patients must have an Expanded Disability Status Scale score of 4 to 7, which corresponds to: 4 = able to walk about 500 yards without aid or rest, up to 7 = using a wheelchair or unable to walk more than five yards.
2
Ongoing treatment monitoring after the initial trial: after a 2–4 week trial, patients with a clear benefit continue taking fampridine for as long as it remains effective, with regular reviews to monitor progress.
3
England’s eligible population for the treatment: while there are more than 120,000 people living with MS in England, only about 5,000 per year are expected to be eligible based on walking impairment.
4
Personal impact context from a patient who previously paid privately: Aysen Slack described how her mobility had decreased and noted the potential for a significant difference if she could improve her walking; Slack had previously funded the drug privately due to cost.
NHS England is making fampridine available to thousands of multiple sclerosis patients, marking the first time a drug proven to improve walking ability will be offered on the health service in England. The twice-daily pill, also known as Fampyra, is expected to help around 5,000 eligible patients in its first year, according to The Independent.
Clinical trials show about 43% of users walk faster and for longer after taking the drug. Fampridine works like a signal booster, helping nerve messages travel more effectively to muscles. The rollout ends years of frustration for patients in England who paid privately while the drug was already available on the NHS in Wales, Scotland, and Northern Ireland.
How Fampridine Works and Who Can Get It
Fampridine is a pill taken twice a day. It acts as a signal booster inside the nervous system. Damaged nerves in MS struggle to carry messages to muscles. The drug helps those signals get through, making walking easier for some patients, according to KMFM.
Not every MS patient qualifies. Eligibility is based on a walking impairment score called the EDSS. Patients must score between 4 and 7. A score of 4 means a person can walk about 500 yards without aid. A score of 7 means they use a wheelchair or can walk no more than five yards. More than 120,000 people in England live with MS, but only around 5,000 per year meet the walking criteria, Radio Royal reported.
A Trial Period Before Long-Term Prescriptions Begin
Patients will not receive a permanent prescription straight away. Doctors will first run a 2 to 4 week trial of the drug. During that time, patients are assessed to see if their walking clearly improves. Only those who show a real benefit will continue taking fampridine long term, according to This Is The Coast.
Those who do continue will have regular reviews to check the drug is still working. If fampridine stops being effective, treatment will stop. This careful monitoring approach is designed to make sure NHS resources go to patients who are actually getting a benefit.
Patients Who Paid Privately Finally Get NHS Access
For years, some MS patients in England paid out of their own pockets for fampridine because the NHS had previously rejected it on value-for-money grounds. Aysen Slack was one of them. She described how her mobility had decreased over time and said the NHS rollout could make a significant difference to her daily life and social independence, according to The Independent.
The drug has been available through NHS services in Wales, Scotland, and Northern Ireland for some time. England's approval closes a long-standing gap. NHS officials have described fampridine as a meaningful advance for people struggling with walking difficulties caused by MS, Conservative Post reported.
What This Means for MS Patients Day to Day
Walking ability is closely tied to independence. For MS patients, losing the ability to walk even short distances affects work, social life, and mental health. A drug that helps 43 in every 100 users walk faster and farther is a major step, even if it does not work for everyone.
Aysen Slack put it plainly — being able to walk better could change how she moves through her day and engages with the world around her. NHS England's decision means patients no longer need private funds to find out if fampridine could work for them. Doctors can now refer eligible patients directly.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
13
Articles
29
Reach
42
A
AnonymousAuthor